Elevated lipoprotein(A) has incremental prognostic value in type 2 diabetic patients with symptomatic coronary artery disease

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 5, 2015, Pages 527-534

  Kwon, Sung Woo ^a,b   Kim, Jong Youn ^c   Sung, Ji Min ^d   Yoon, Young Won ^c   Rhee, Ji Hyuck ^e   Lee, Byoung Kwon ^c   Jung, Young Hak ^c   Kim, Ki Hyun ^c   Cha, Jung Joon ^c   Park, Jong Kwan ^f   Choi, Eui Young ^c   Hong, Bum Kee ^c   Rim, Se Joong ^c   Kwon, Hyuck Moon ^c  

^a Inha University Hospital   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d CHA University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f National Health Insurance Corporation   (South Korea)

Author keywords

Adverse cardiac events; Coronary artery disease; Diabetes; Lipoprotein(a); Prognosis

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; COLORIMETRY; CORONARY ARTERY DISEASE; DEATH; FEMALE; HEART INFARCTION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; TURBIDIMETRY; AGED; BLOOD; COMPLICATION; MIDDLE AGED;

AGED; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROGNOSIS;

EID: 84929398911     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.25551     Document Type: Article

References (26)

1. 1) Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis. JAMA, 2002; 287: 2570-2581
2. 2) Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13000 men and women with 20 years of follow-up. Arch Intern Med, 2004; 164: 1422-1426
3. 3) Berglund L, Ramakrishnan R: Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol, 2004; 24: 2219-2226
4. 4) Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation, 2000; 102: 1082-1085
5. 5) Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart. JAMA, 2009; 302: 412-423
6. 6) Murase T, Okubo M, Amemiya-Kudo M, Ebara T, Mori Y: Impact of elevated serum lipoprotein(a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. Metabolism, 2008; 57: 791-795
7. 7) Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM: Lipoprotein(a) and risk of type 2 diabetes. Clin Chem, 2010; 56: 1252-1260
8. 8) Kwon SW, Lee BK, Hong BK, Kim JY, Choi EY, Sung JM, Rhee JH, Park YM, Ma DW, Chung H, Mun HS, Lee SJ, Park JK, Min PK, Yoon YW, Rim SJ, Kwon HM: Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients. Int J Cardiol, 2013; 167: 1990-1994
9. 9) Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med, 2008; 27: 157-172
10. 10) Pencina MJ, D’Agostino RB Sr., Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med, 2011; 30: 11-21
11. 11) Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG: Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation, 2008; 117: 176-184
12. 12) Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 2005; 352: 1293-1304
13. 13) Rainwater DL, Haffner SM: Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol, 1998; 18: 1335-1341
14. 14) Chien KL, Lee YT, Sung FC, Su TC, Hsu HC, Lin RS: Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis, 1999; 143: 267-273
15. 15) Sung KC, Wild SH, Byrne CD: Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutr Metab Cardiovasc Dis, 2013; 23: 1239-1246
16. 16) Mohan V, Deepa R, Haranath SP, Premalatha G, Rema M, Sastry NG, Enas EA: Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in South India. Diabetes Care, 1998; 21: 1819-1823
17. 17) Gazzaruso C, Garzaniti A, Falcone C, Geroldi D, Finardi G, Fratino P: Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects. Diabet Med, 2001; 18: 589-594
18. 18) James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D: Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia, 1995; 38: 711-714
19. 19) Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P, Chapman J, Passa P: Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia, 1994; 37: 585-591
20. 20) Watts GF, ap Gwilym RM, Mazurkiewicz J, Coltart J: Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM. Diabetes Care, 1995; 18: 234-236
21. 21) Pedreño J, Fernández R, Ballester A, Jornet A, Usón M, Canela J, Petit M: Lack of association of serum lipoprotein (a) levels with type-2 diabetes mellitus in patients with angiographically defined coronary artery disease. Int J Cardiol, 2000; 74: 159-167
22. 22) Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, Murase T: Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care, 1995; 18: 241-244
23. 23) Hernández C, Francisco G, Chacón P, Simó R: Lipoprotein(a) as a risk factor for cardiovascular mortality in type 2 diabetic patients: a 10-year follow-up study. Diabetes Care, 2005; 28: 931-933
24. 24) Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L: Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J, 2012; 33: 325-334
25. 25) Abu-Lebdeh HS, Hodge DO, Nguyen TT: Predictors of macrovascular disease in patients with type 2 diabetes mellitus. Mayo Clin Proc, 2001; 76: 707-712
26. 26) Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H: Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Invest, 2006; 36: 91-97